NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
November 17 meeting will address Phase 2 study design and potential regulatory pathwaysCALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervo…